Axsome Therapeutics Change To Liabilities Over Time

AXSM Stock  USD 87.01  0.06  0.07%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Axsome Therapeutics Performance and Axsome Therapeutics Correlation.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
  
As of the 24th of December 2024, Change To Liabilities is likely to grow to about 30.7 M.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.58)
Revenue Per Share
7.108
Quarterly Revenue Growth
0.813
Return On Assets
(0.26)
Return On Equity
(1.72)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Change To Liabilities Analysis

Compare Axsome Therapeutics and related stocks such as Incyte, ImmunoGen, and Sarepta Therapeutics Change To Liabilities Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
INCY(44.8 M)(44.8 M)(65.6 M)(33.7 M)28 M18 M57.7 M79.8 M24.1 M58.9 M129 M204.8 M325.6 M374.5 M393.2 M
SRPT683 K9.5 M9.5 M9.5 M10.8 M18.3 M7.3 M12.9 M90.2 M123 M749.4 M(89.2 M)58.3 M67.1 M78.2 M
ACAD919 K99 K(2.8 M)MMM4.9 M2.2 M11.7 M12 M31.2 M(8.2 M)5.9 M6.8 M5.7 M
MDGL(4.5 M)(4.5 M)4.6 M7.2 M(1.1 M)(8.5 M)(2.4 M)M(1.6 M)15.5 M21.4 M20.4 M38.9 M44.7 M46.9 M
MCRB810 K810 K810 K810 K810 K5.6 M117.4 M(10.6 M)379 K(4.4 M)2.6 MM2.2 MM1.9 M
TGTX243 K415.4 K2.6 M3.9 M(850.3 K)5.3 M6.3 M10.9 M29.2 M23.8 M(22 M)(2.3 M)(11.2 M)(12.9 M)(12.3 M)
TERN488 K488 K488 K488 K488 K488 K488 K488 K488 K628 K(453 K)1.7 M694 K798.1 K678.5 K
HEPA3.1 M3.1 M3.1 M3.1 M3.1 M3.1 M(2.1 M)(390.5 K)(897.7 K)(424.4 K)M(1.1 M)2.2 M2.6 M2.7 M
AKRO65.5 K65.5 K65.5 K65.5 K65.5 K65.5 K65.5 K65.5 K1.3 M(426 K)2.5 M12 M(6.4 M)(7.3 M)(7 M)
DAWN14 K14 K14 K14 K14 K14 K14 K14 K14 K14 K132 K6.7 M7.8 M8.9 M9.4 M
BPMC1.1 M1.1 M1.1 M1.1 M2.4 M17 M39.4 M4.3 M24.4 M38.4 M15.4 M10.3 M3.6 M4.1 M3.9 M
PDSB(20.3 K)(20.3 K)(20.3 K)(20.3 K)(20.3 K)(20.3 K)(20.3 K)226.8 K788.8 K(2 M)217.5 K(105.8 K)M6.9 M7.3 M

Axsome Therapeutics and related stocks such as Incyte, ImmunoGen, and Sarepta Therapeutics Change To Liabilities description

My Equities

My Current Equities and Potential Positions

Axsome Therapeutics
AXSM
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationNew York; U.S.A
ExchangeNASDAQ Exchange
USD 87.01
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out Axsome Therapeutics Performance and Axsome Therapeutics Correlation.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Axsome Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Axsome Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Axsome Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...